{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T14:04:19Z","timestamp":1784642659964,"version":"3.55.0"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.bone.2023.116992","type":"journal-article","created":{"date-parts":[[2023,12,21]],"date-time":"2023-12-21T13:11:41Z","timestamp":1703164301000},"page":"116992","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Bone mineral density, vitamin D and osseous metabolism indices in neurofibromatosis type 1: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"180","author":[{"given":"Angelos","family":"Kaspiris","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elias","family":"Vasiliadis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilias D.","family":"Iliopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fotis","family":"Panagopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitra","family":"Melissaridou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioanna","family":"Lianou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Ntourantonis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga D.","family":"Savvidou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelia","family":"Papadimitriou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Spiros G.","family":"Pneumaticos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bone.2023.116992_bb0005","first-page":"285","article-title":"Neurofibromatosis type 1: a common familial cancer syndrome","volume":"92","author":"Upadhyaya","year":"2004","journal-title":"Methods Mol. Med."},{"issue":"2","key":"10.1016\/j.bone.2023.116992_bb0010","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/ajmg.a.33139","article-title":"Birth incidence and prevalence of tumor-prone syndromes: estimates from a UK family genetic register service","volume":"152A","author":"Evans","year":"2010","journal-title":"Am. J. Med. Genet. A"},{"key":"10.1016\/j.bone.2023.116992_bb0015","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/978-1-60761-795-2_27","article-title":"Mutational and functional analysis in human Ras\/MAP kinase genetic syndromes","volume":"661","author":"Tidyman","year":"2010","journal-title":"Methods Mol. Biol."},{"issue":"5","key":"10.1016\/j.bone.2023.116992_bb0020","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/nrc3911","article-title":"A RASopathy gene commonly mutated in cancer: the neurofibromatosis type 1 tumour suppressor","volume":"15","author":"Ratner","year":"2015","journal-title":"Nat. Rev. Cancer"},{"issue":"8","key":"10.1016\/j.bone.2023.116992_bb0025","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1038\/s41436-021-01170-5","article-title":"Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation","volume":"23","author":"Legius","year":"2021","journal-title":"Genet Med"},{"issue":"5","key":"10.1016\/j.bone.2023.116992_bb0030","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1002\/(SICI)1096-8628(19990611)84:5<413::AID-AJMG5>3.0.CO;2-1","article-title":"Descriptive analysis of tibial pseudarthrosis in patients with neurofibromatosis 1","volume":"84","author":"Stevenson","year":"1999","journal-title":"Am. J. Med. Genet."},{"issue":"17","key":"10.1016\/j.bone.2023.116992_bb0035","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1002\/ajmg.a.31758","article-title":"Neurofibromatosis type 1 is a genetic skeletal disorder","volume":"143A","author":"Stevenson","year":"2007","journal-title":"Am. J. Med. Genet. A"},{"issue":"1","key":"10.1016\/j.bone.2023.116992_bb0040","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s12031-019-01277-0","article-title":"NF1 somatic mutation in dystrophic scoliosis","volume":"68","author":"Margraf","year":"2019","journal-title":"J. Mol. Neurosci."},{"issue":"2","key":"10.1016\/j.bone.2023.116992_bb0045","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1007\/s00223-023-01094-z","article-title":"Bone mineral density in neurofibromatosis type 1: a systematic review and meta-analysis","volume":"113","author":"Charoenngam","year":"2023","journal-title":"Calcif. Tissue Int."},{"issue":"1","key":"10.1016\/j.bone.2023.116992_bb0050","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s00198-009-0933-y","article-title":"High bone turnover and accumulation of osteoid in patients with neurofibromatosis 1","volume":"21","author":"Seitz","year":"2010","journal-title":"Osteoporos. Int."},{"issue":"23","key":"10.1016\/j.bone.2023.116992_bb0055","doi-asserted-by":"crossref","first-page":"2770","DOI":"10.1097\/00007632-199712010-00014","article-title":"Spine update. The management of scoliosis in neurofibromatosis","volume":"22","author":"Kim","year":"1997","journal-title":"Spine (Phila Pa 1976)"},{"issue":"2","key":"10.1016\/j.bone.2023.116992_bb0060","first-page":"88","article-title":"Surgical treatment of scoliosis caused by neurofibromatosis type 1","volume":"20","author":"Shen","year":"2005","journal-title":"Chin. Med. Sci. J."},{"issue":"11","key":"10.1016\/j.bone.2023.116992_bb0065","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1002\/jbmr.1685","article-title":"A controlled register-based study of 460 neurofibromatosis 1 patients: increased fracture risk in children and adults over 41 years of age","volume":"27","author":"Heerv\u00e4","year":"2012","journal-title":"J. Bone Miner. Res."},{"issue":"5","key":"10.1016\/j.bone.2023.116992_bb0070","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1080\/14728222.2018.1465931","article-title":"Emerging therapeutic targets for neurofibromatosis type 1","volume":"22","author":"Walker","year":"2018","journal-title":"Expert Opin. Ther. Targets"},{"issue":"10","key":"10.1016\/j.bone.2023.116992_bb0075","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1136\/jmg.2006.041095","article-title":"Vitamin D deficiency associated with number of neurofibromas in neurofibromatosis 1","volume":"43","author":"Lammert","year":"2006","journal-title":"J. Med. Genet."},{"issue":"2","key":"10.1016\/j.bone.2023.116992_bb0080","doi-asserted-by":"crossref","first-page":"255","DOI":"10.3390\/metabo13020255","article-title":"Vitamin D and bone metabolism in adult patients with Neurofibromatosis type 1","volume":"13","author":"Modica","year":"2023","journal-title":"Metabolites"},{"issue":"4","key":"10.1016\/j.bone.2023.116992_bb0085","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s00403-011-1191-3","article-title":"Bone mineral metabolism in patients with neurofibromatosis type 1 (von Recklingausen disease)","volume":"304","author":"Petramala","year":"2012","journal-title":"Arch. Dermatol. Res."},{"issue":"1","key":"10.1016\/j.bone.2023.116992_bb0090","doi-asserted-by":"crossref","first-page":"4368","DOI":"10.1038\/s41598-022-07855-4","article-title":"Bone metabolism in patients with type 1 neurofibromatosis: key role of sun exposure and physical activity","volume":"12","author":"Ferrara","year":"2022","journal-title":"Sci. Rep."},{"issue":"9","key":"10.1016\/j.bone.2023.116992_bb0095","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.braindev.2008.02.002","article-title":"Bone metabolism markers and bone mineral density in children with neurofibromatosis type 1","volume":"30","author":"Duman","year":"2008","journal-title":"Brain Dev."},{"issue":"7","key":"10.1016\/j.bone.2023.116992_bb0100","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1002\/ajmg.a.36001","article-title":"The generalized bone phenotype in children with neurofibromatosis 1: a sibling matched case-control study","volume":"161A","author":"Armstrong","year":"2013","journal-title":"Am. J. Med. Genet. A"},{"key":"10.1016\/j.bone.2023.116992_bb0105","article-title":"Vitamin D status and VDR genotype in NF1 patients: a case-control study from southern Brazil. Int","volume":"2015","author":"Souza Mario Bueno","year":"2015","journal-title":"J. Endocrinol."},{"issue":"1","key":"10.1016\/j.bone.2023.116992_bb0110","first-page":"111","article-title":"Vitamin D status and muscle function in children with neurofibromatosis type 1 (NF1)","volume":"13","author":"Hockett","year":"2013","journal-title":"Musculoskelet Neuronal Interact."},{"issue":"6","key":"10.1016\/j.bone.2023.116992_bb0115","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1007\/s00223-021-00807-6","article-title":"Bone status according to neurofibromatosis type 1 phenotype: a descriptive study of 60 women in France","volume":"108","author":"Jalabert","year":"2021","journal-title":"Calcif. Tissue Int."},{"issue":"3\u20134","key":"10.1016\/j.bone.2023.116992_bb0120","first-page":"169","article-title":"Pediatric 25-hydroxyvitamin D concentrations in neurofibromatosis type 1","volume":"24","author":"Stevenson","year":"2011","journal-title":"J. Pediatr. Endocrinol. Metab."},{"issue":"5","key":"10.1016\/j.bone.2023.116992_bb0125","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.ijsu.2010.02.007","article-title":"Preferred reporting items for systematic reviews and me-ta-analyses: the PRISMA statement","volume":"8","author":"Moher","year":"2010","journal-title":"Int. J. Surg."},{"key":"10.1016\/j.bone.2023.116992_bb0130","article-title":"The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses","author":"Wells","year":"2000","journal-title":"Ottawa Health Research Institute."},{"issue":"3","key":"10.1016\/j.bone.2023.116992_bb0135","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1159\/000051263","article-title":"Interrater reliability of the modified Jadad quality scale for systematic reviews of Alzheimer\u2019s disease drug trials","volume":"12","author":"Oremus","year":"2001","journal-title":"Dement. Geriatr. Cogn. Disord."},{"issue":"5","key":"10.1016\/j.bone.2023.116992_bb0140","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1590\/1806-9282.66.5.666","article-title":"Reduced bone mineral content and density in neurofibromatosis type 1 and its association with nutrient intake","volume":"66","author":"Souza","year":"2020","journal-title":"Rev. Assoc. Med. Bras. (1992)"},{"issue":"2","key":"10.1016\/j.bone.2023.116992_bb0145","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s00223-018-0488-z","article-title":"Trabecular bone score (TBS) and bone metabolism in patients affected with type 1 neurofibromatosis (NF1)","volume":"104","author":"Filopanti","year":"2019","journal-title":"Calcif. Tissue Int."},{"issue":"1","key":"10.1016\/j.bone.2023.116992_bb0150","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jpeds.2006.10.048","article-title":"Bone mineral density in children and adolescents with neurofibromatosis type 1","volume":"150","author":"Stevenson","year":"2007","journal-title":"J. Pediatr."},{"issue":"8","key":"10.1016\/j.bone.2023.116992_bb0155","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1002\/jbmr.4633","article-title":"Identifying bone matrix impairments in a mouse model of neurofibromatosis type 1 (NF1) by clinically translatable techniques","volume":"37","author":"Ahmed","year":"2022","journal-title":"J. Bone Miner. Res."},{"issue":"4","key":"10.1016\/j.bone.2023.116992_bb0160","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.bone.2007.11.006","article-title":"Recent insights into bone development, homeostasis, and repair in type 1 neurofibromatosis (NF1)","volume":"42","author":"Schindeler","year":"2008","journal-title":"Bone"},{"key":"10.1016\/j.bone.2023.116992_bb0165","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.bone.2017.10.012","article-title":"The reduced osteogenic potential of Nf1-deficient osteoprogenitors is EGFR-independent","volume":"106","author":"Tahaei","year":"2018","journal-title":"Bone"},{"issue":"19","key":"10.1016\/j.bone.2023.116992_bb0170","doi-asserted-by":"crossref","first-page":"11524","DOI":"10.1111\/jcmm.15767","article-title":"The neurofibromatosis type I gene promotes autophagy via mTORC1 signalling pathway to enhance new bone formation after fracture","volume":"24","author":"Tan","year":"2020","journal-title":"J. Cell. Mol. Med."},{"issue":"20","key":"10.1016\/j.bone.2023.116992_bb0175","doi-asserted-by":"crossref","first-page":"3910","DOI":"10.1093\/hmg\/ddr310","article-title":"Mice lacking Nf1 in osteochondroprogenitor cells display skeletal dysplasia similar to patients with neurofibromatosis type I","volume":"20","author":"Wang","year":"2011","journal-title":"Hum. Mol. Genet."},{"issue":"6","key":"10.1016\/j.bone.2023.116992_bb0180","first-page":"1378","article-title":"Hyperactive transforming growth factor-\u03b21 signaling potentiates skeletal defects in a neurofibromatosis type 1 mouse model","volume":"48","author":"Rhodes","year":"2011","journal-title":"Bone"},{"issue":"6","key":"10.1016\/j.bone.2023.116992_bb0185","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1530\/ERC-12-0293","article-title":"Bone mineral density in children and young adults with neurofibromatosis type 1","volume":"19","author":"Lodish","year":"2012","journal-title":"Endocr. Relat. Cancer"},{"issue":"8","key":"10.1016\/j.bone.2023.116992_bb0190","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1111\/j.1651-2227.2007.00401.x","article-title":"Bone mineral density in children with neurofibromatosis 1","volume":"96","author":"Yilmaz","year":"2007","journal-title":"Acta Paediatr."},{"issue":"10","key":"10.1016\/j.bone.2023.116992_bb0195","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1007\/s001980170032","article-title":"Decreased bone mineral density in neurofibromatosis-1 patients with spinal deformities","volume":"12","author":"Ill\u00e9s","year":"2001","journal-title":"Osteoporos. Int."},{"issue":"4","key":"10.1016\/j.bone.2023.116992_bb0200","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1097\/01.bpb.0000271310.87997.ae","article-title":"Decreased bone mineral density in neurofibromatosis type 1: results from a pediatric cohort","volume":"27","author":"Dulai","year":"2007","journal-title":"J. Pediatr. Orthop."},{"issue":"1","key":"10.1016\/j.bone.2023.116992_bb0205","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.ymgme.2007.12.004","article-title":"Generalized metabolic bone disease in neurofibromatosis type I","volume":"94","author":"Brunetti-Pierri","year":"2008","journal-title":"Mol. Genet. Metab."},{"issue":"2","key":"10.1016\/j.bone.2023.116992_bb0210","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1515\/jpem-2016-0092","article-title":"Bone mineral density and bone metabolic markers\u2019 status in children with neurofibromatosis type 1","volume":"30","author":"Poyrazo\u011flu","year":"2017","journal-title":"J. Pediatr. Endocrinol. Metab."},{"issue":"2","key":"10.1016\/j.bone.2023.116992_bb0215","first-page":"175","article-title":"A controlled register-based study of 460 neurofibromatosis 1 patients: increased fracture risk in children and adults over 41 years of age","volume":"30","author":"Heerv\u00e4","year":"2017","journal-title":"J. Pediatr. Endocrinol. Metab."},{"issue":"1","key":"10.1016\/j.bone.2023.116992_bb0220","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s11657-018-0507-8","article-title":"Progressive bone impairment with age and pubertal development in neurofibromatosis type I","volume":"13","author":"Rodari","year":"2018","journal-title":"Arch. Osteoporos."},{"issue":"7\u20138","key":"10.1016\/j.bone.2023.116992_bb0225","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.clinbiochem.2014.02.020","article-title":"Differences of 25-hydroxyvitamin D3 concentrations in children and adults with neurofibromatosis type 1","volume":"47","author":"Schnabel","year":"2014","journal-title":"Clin. Biochem."},{"issue":"4","key":"10.1016\/j.bone.2023.116992_bb0230","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1136\/jmg.2008.061895","article-title":"Bone health and fracture rate in individuals with neurofibromatosis 1 (NF1)","volume":"46","author":"Tucker","year":"2009","journal-title":"J. Med. Genet."},{"issue":"6","key":"10.1016\/j.bone.2023.116992_bb0235","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1007\/s00223-013-9835-2","article-title":"Follow-up of six patients with neurofibromatosis 1-related osteoporosis treated with alendronate for 23 months","volume":"94","author":"Heerv\u00e4","year":"2014","journal-title":"Calcif. Tissue Int."},{"issue":"11","key":"10.1016\/j.bone.2023.116992_bb0240","doi-asserted-by":"crossref","first-page":"2880","DOI":"10.1172\/JCI29092","article-title":"Hyperactivation of p21ras and PI3K cooperate to alter murine and human neurofibromatosis type 1-haploinsufficient osteoclast functions","volume":"116","author":"Yang","year":"2006","journal-title":"J. Clin. Invest."},{"issue":"2","key":"10.1016\/j.bone.2023.116992_bb0245","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1007\/s11033-020-06128-5","article-title":"Signaling pathways in human osteoclasts differentiation: ERK1\/2 as a key player","volume":"48","author":"Pennanen","year":"2021","journal-title":"Mol. Biol. Rep."},{"issue":"23","key":"10.1016\/j.bone.2023.116992_bb0250","doi-asserted-by":"crossref","first-page":"4818","DOI":"10.1093\/hmg\/ddt333","article-title":"Hyperactive Ras\/MAPK signaling is critical for tibial nonunion fracture in neurofibromin-deficient mice","volume":"22","author":"Sharma","year":"2013","journal-title":"Hum. Mol. Genet."},{"issue":"1","key":"10.1016\/j.bone.2023.116992_bb0255","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/jbmr.528","article-title":"A murine model of neurofibromatosis type 1 tibial pseudarthrosis featuring proliferative fibrous tissue and osteoclast-like cells","volume":"27","author":"El-Hoss","year":"2012","journal-title":"J. Bone Miner. Res."},{"issue":"5","key":"10.1016\/j.bone.2023.116992_bb0260","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.bone.2005.01.022","article-title":"Neurofibromin and its inactivation of Ras are prerequisites for osteoblast functioning","volume":"36","author":"Yu","year":"2005","journal-title":"Bone"}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328223003253?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328223003253?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T18:06:43Z","timestamp":1757614003000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328223003253"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":52,"alternative-id":["S8756328223003253"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2023.116992","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bone mineral density, vitamin D and osseous metabolism indices in neurofibromatosis type 1: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Bone","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bone.2023.116992","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"116992"}}